Circulating Dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept

Journal of Rheumatology

Volumn 35, Issue 12, 2008, Pages 2313-2315

  Garnero, Patrick ^a,b   Tabassi, Nadine Charni Ben ^b   Voorzanger Rousselot, Nathalie ^b  

^a INSERM   (France)

^b Synarc   (France)

Author keywords

Bone erosion; Dickkopf 1; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; DICKKOPF 1 PROTEIN; ETANERCEPT; METHOTREXATE;

ADULT; ARTICLE; BONE EROSION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; FEMALE; FOOT; HAND; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIODIAGNOSIS; RHEUMATOID ARTHRITIS; SCORING SYSTEM; WRIST;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RISK; SEVERITY OF ILLNESS INDEX;

EID: 57349120155     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080356     Document Type: Article

References (12)

1. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nature Med 2007;13:156-63.
2. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
3. Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide are associated with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:21-3.
4. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
5. Sharp JT, Lidsky MD, Collins LS, Moreland J. Methods of scoring the progression of radiological changes in rheumatoid arthritis: correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971;14:706-20.
6. van der Heijde DM, van Riel PL, van Leeuwen MA, van Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective study of 147 patients. Br J Rheumatol 1992;31:519-25.
7. Voorzanger-Rousselot N, Journe F, Maitzen S, et al. Evaluation of a new two site-Elisa for serum Dkk-1 in patients with breast cancer and bone metastases [abstract]. Calcif Tissue Int 2007;80:S71.
8. Landewé R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119-25.
9. Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000;43:2143-51.
10. Geusens P, Landewé R, Garnero P, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006;54:1772-7.
11. Kearns AE, Khosla S, Kostenuik P. Receptor activator of nuclear factor-κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008;29:155-92.
12. Lane NE, Nevitt MC, Lui LY, de Leon P, Corr M. Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian women. Arthritis Rheum 2007;56:3319-25.